ChromaDex Corporation (CDXC) Skyrocketed to $3.99

ChromaDex Corporation (NASDAQ:CDXC) Corporate Logo

ChromaDex Corporation (NASDAQ:CDXC) increased considerably to $3.99. It was posted on Mar, 14 by The company has $220.59M market cap. The valuation of NASDAQ:CDXC can change by $11.03M if our $4.19 target is touched.

For more ChromaDex Corporation (NASDAQ:CDXC) news released briefly go to:,,, or The titles are as follows: “New Study Shows Supplementation with Nicotinamide Riboside (NR) During Breastfeeding Yields Measurable, Lasting Benefits to Mothers and Offspring in Animal Model – Nasdaq” released on January 23, 2019, “TRU NIAGEN® Expands North American Footprint with Product Launch in Canada – GlobeNewswire” on December 17, 2018, “Benzinga’s Top Upgrades, Downgrades For February 14, 2019 – Benzinga” with a publish date: February 14, 2019, “ChromaDex Brings TRU NIAGEN® to SXSW® 2019 Nasdaq:CDXC – GlobeNewswire” and the last “ChromaDex to Present at the 31st Annual ROTH Conference – Nasdaq” with publication date: March 11, 2019.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies.The firm is valued at $220.59 million. The firm offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside , a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients.Currently it has negative earnings. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications.

ChromaDex Corporation (NASDAQ:CDXC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.